MIRA INFORM REPORT
|
Report Date : |
16.09.2011 |
IDENTIFICATION DETAILS
|
Name : |
TESS PHARMACEUTICALS CO., LIMITED |
|
|
|
|
Registered Office : |
Marketing Office, Room No. 814,
Zhijiangminglou Building, Xiaoshan District, Hangzhou, Zhejiang Province
310018 Pr |
|
|
|
|
Country : |
China |
|
|
|
|
Date of Incorporation : |
18.07.2008 |
|
|
|
|
Com. Reg. No.: |
1257944 |
|
|
|
|
Legal Form : |
Private company with
Limited Liability |
|
|
|
|
Line of Business : |
Exporting Pharmaceutical Products |
RATING & COMMENTS
|
MIRA’s Rating : |
Ca |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
Status : |
Small Company |
|
|
|
|
Payment
Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2011
|
Country Name |
Previous Rating (31.12.2010) |
Current Rating (31.03.2011) |
|
China |
a2 |
a2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name & address
TESS PHARMACEUTICALS CO., LIMITED
MARKETING OFFICE, ROOM NO. 814,
ZHIJIANGMINGLOU BUILDING
XIAOSHAN DISTRICT, HANGZHOU, ZHEJIANG PROVINCE 310018 PR CHINA
TEL: 86 (0) 571-86877572
FAX: 86 (0) 571-86877572
NARRATIVE
REPORT
This refers to a type of report whose format is different from that of a
standard report. Such type of report is provided when:
l
Information obtained is insufficient for compiling
a standard report.
l
The enquired co has been out of business or its business
address has been untraceable.
It should be noted that the time and manpower spent on preparing such
type of report might be greater than those on a standard report. On many
occasions, the information in this type of report still indicates the current
status of the enquired co. and serves as a useful reference to assess its
credit standing.
------------------------------------------
Adopted abbreviations (as follows)
SC - Subject Company
(the company inquired by you)
N/A – Not available
CNY – China Yuan Ren
Min Bi
CHECK ON SC’S REGISTERED
TELEPHONE LINE
²
According
to the English name, we found the website www.tesspharm.com,
and the contact ways are as follows,
TEL: 86 (0) 571-86877572
FAX: 86 (0) 571-86877572
When we dialed the above telephone number, a lady Ms. Liu
answered the phone. She admitted the English name, and told us the Chinese name
in translation is “泰丝制药有限公司”,
which is registered in Hong Kong, but mainly operating in Hangzhou, Zhejiang
Province, PRC
China, there is no one working in Hong Kong.
²
Ms. Liu introduced
the below information,
A.
SC is mainly engaged in exporting
pharmaceutical products.
B.
SC registered in Hong Kong, which
facilitates its exporting business.
C.
SC’s e-mail is: sales@tesspharm.com
D.
Ms. Liu released that they have an
account in Shenzhen Development Bank Co., Ltd., but refused to release the
details.
E.
Ms. Liu will introduce more information
if we provide the name of client, formal power of attorney, and detailed
products client needs.
OPERATION FROM INTERNET
According to the website,
The
products mainly include:
Entecavir
Monohydrate
Ascorbic
acid
Acyclovir
Atracurium
Besilate
Palonosetron
HCl
Etc.
SC sources its materials 100% from domestic
market, mainly Shandong. SC sells 100% to overseas market, mainly India, etc.
SPOT VISIT
Room
No. 814, Zhijiangminglou Building, Xiaoshan District, Hangzhou, Zhejiang
Province 310018 PR China
Ms. Liu released that SC is currently working there.
REGISTRATION
According to the Chinese name “泰丝制药有限公司” Ms. Liu released and the key words “泰丝制药”, a research was conducted with Hangzhou municipal & Zhejiang Provincial Administration of Industry & Commerce (the official body of issuing and renewing business license), but no record of SC was found.
During our check with Hong Kong Registry, we found the following registration about SC,
Company Name: Tess Pharmaceuticals Co., Limited
Company File No.: 1257944
Date of Registration:
July 18, 2008
Legal Form: Private
Status: Live
CONCLUSIONS
SC is considered small-sized in its line with 3 years business history.
Credit dealings with SC should be confined into C.O.D. to small amount at
present.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.47.84 |
|
UK Pound |
1 |
Rs.75.40 |
|
Euro |
1 |
Rs.65.68 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.